CSIMarket
 


Momenta Pharmaceuticals inc   (MNTA)
Other Ticker:  
 

Cumulative Momenta Pharmaceuticals Inc 's Working Capital Ratio for Trailing Twelve Months Period

MNTA's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

MNTA Working Capital Ratio for Trailing Twelve Months Period

(Jun 30 2020)
II. Quarter
(Mar 31 2020)
I. Quarter
(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
(Mar 31 2019)
I. Quarter
Y / Y Current Liabilities Growth 39.06 % 61.44 % -25.46 % -15.49 % 93.73 %
Y / Y Current Assets Growth 32.08 % 11.08 % -2.73 % -3.46 % 2.36 %
Working Capital Ratio for Trailing Twelve Months Period 6.54 6.63 7.5 7.02 6.82
Total Ranking # 549 # 542 # 465 # 455 # 517
Seq. Current Liabilities Growth -13.75 % 104.92 % -2.81 % -19.05 % 0.13 %
Seq. Current Assets Growth -6.73 % 71.37 % -9.76 % -8.43 % -21.55 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Jun 30 2020
On the trailing twelve months basis Due to fall in Current Liabilities in the II. Quarter to $72 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 6.54 below Momenta Pharmaceuticals Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 51 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Momenta Pharmaceuticals Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about MNTA
Working Capital Ratio MNTA in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 52
Sector # 267
S&P 500 # 543


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
15.5 8.65 4.45
(Dec 31 2013)   (Sep 30 2017)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Jun 30 2020, within Biotechnology & Pharmaceuticals Industry Working Capital Ratio for Trailing Twelve Months Period
Palisade Bio Inc   16.90 
Aptose Biosciences Inc   16.44 
Adverum Biotechnologies Inc   16.28 
Audentes Therapeutics Inc   16.16 
Avrobio Inc   15.53 
Prevail Therapeutics Inc   15.42 
Acceleron Pharma inc  15.41 
Voyager Therapeutics Inc   15.26 
Iovance Biotherapeutics Inc   15.21 
Crispr Therapeutics Ag  14.70 
Organovo Holdings Inc   13.81 
Logicbio Therapeutics Inc   13.69 
Cortexyme Inc   13.68 
Moderna Inc   13.32 
Axcella Health Inc   12.53 
Immunovant Inc   12.40 
Allovir Inc   12.03 
Checkmate Pharmaceuticals Inc   11.95 
Regenxbio Inc   11.27 
Denali Therapeutics Inc   11.02 
Fennec Pharmaceuticals Inc   11.00 
China Biologic Products Holdings Inc   10.89 
Ladrx Corporation  10.68 
Orchard Therapeutics Plc  10.55 
Adma Biologics Inc   10.05 
Compugen Ltd  10.04 
Surface Oncology Inc   9.41 
Atara Biotherapeutics Inc   9.11 
Adaptimmune Therapeutics Plc  8.84 
Adaptive Biotechnologies Corporation  8.79 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com